Arrhythmias & electrophysiologyCohort study

Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis

Ann Intern MedPublished

  • Observational cohort study using target trial emulation
  • population-wide insurance claims data in Taiwan

Authors' conclusion

In Asian patients with AF-MS, DOACs were associated with an increased 1-year risk for stroke but a decreased risk for MI compared with warfarin.

Study context

Population
Patients diagnosed with atrial fibrillation and mitral stenosis (AF-MS) and prescribed either direct oral anticoagulants (DOACs) or warfarin between 1 January 2011 and 31 December 2021
Exposure
DOACs versus warfarin

Main finding

As reported in the abstract

Ischemic stroke · 1-year follow-up
DOACs vs warfarinRD, percentage points (95% CI)
increased risk with DOACs
4.97(1.27–8.57)
DOACs vs warfarinRelative risk (CI)
Ischemic stroke
1.22(1.05–1.41)

Observational data: associations, not effects.

Further findings

OutcomeRD (percentage points) (CI)
Composite stroke · 1-year follow-up — DOACs vs warfarin · increased risk with DOACs5.56 (1.77–8.97)
MI · 1-year follow-up — DOACs vs warfarin · decreased risk with DOACs−1.61 (−3.17 to −0.03)
OutcomeRR (CI)
Composite stroke · 1-year follow-up — DOACs vs warfarin1.23 (1.07–1.42)
MI · 1-year follow-up — DOACs vs warfarin0.61 (0.37–0.99)

All-cause death

The 2 groups did not differ in risks for all-cause death

Ischemic stroke with rivaroxaban · short- and long-term follow-up

Rivaroxaban increased the risk for ischemic stroke during both short- and long-term follow-up periods

Original publication

Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis. Ann Intern Med. Published 11 August 2026. doi:10.7326/annals-25-04740

Summarised from the published abstract; every number is checked against it